aliskiren vs enalapril
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of aliskiren and enalapril. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not coadminister aliskiren with enalapril maleate in patients with diabetes. Avoid use of aliskiren with enalapril maleate in patients with renal impairment (GFR <60 mL/min).
Tekturna is a medicine used to treat high blood pressure. It helps lower blood pressure, which can reduce the risk of strokes and heart attacks.
Enalapril (Vasotec) is a medicine that lowers blood pressure and helps treat heart failure. It belongs to a class of drugs called ACE inhibitors.
Tekturna is used to treat high blood pressure in adults and children who weigh at least 110 pounds and are 6 years or older. Lowering your blood pressure helps prevent strokes and heart attacks. It is important to manage high blood pressure with a healthy lifestyle too.
Enalapril is used to treat high blood pressure. It can be used alone or with other blood pressure medicines, like water pills. Enalapril also treats symptomatic congestive heart failure, usually with other medicines. It can also help clinically stable patients with left ventricular dysfunction.
Tekturna works by blocking a substance in your body called renin. Renin helps to control your blood pressure. By blocking renin, Tekturna helps to lower your blood pressure.
Enalapril blocks a substance in your body that tightens blood vessels. This helps your blood vessels relax and widens them. As a result, blood pressure is lowered, and blood can flow more easily.
- • Diarrhea
- • Headache
- • Dizziness
- • Fatigue
- • Cough
- Asthenia 367
- Fall 356
- Nausea 336
- Dyspnoea 315
- Headache 301
- Diarrhoea 2,807
- Dyspnoea 2,659
- Nausea 2,574
- Fatigue 2,377
- Drug Interaction 2,336
Tekturna can harm your unborn baby, even causing death. If you become pregnant, stop taking Tekturna right away and tell your doctor.
This drug can harm your unborn baby. Stop taking enalapril as soon as you know you are pregnant.
Tekturna can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, talk to your doctor about other blood pressure medicines. Breastfeeding is not recommended while taking Tekturna.
Do not take enalapril if you are pregnant because it can cause harm or death to the developing fetus. Talk to your doctor about safe alternatives if you are breastfeeding.
Also Compare, Nearby Drugs
Compare enalapril with
How to Read This aliskiren vs enalapril Comparison
aliskiren is classified in the Direct Renin Inhibitor drug class, while enalapril sits within the ACE Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aliskiren has 1,675 submissions while enalapril has 12,753. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to both drugs work on the same system to lower blood pressure, which can lead to dangerously low blood pressure or kidney damage.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aliskiren or enalapril.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.